2 August 2017

Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update

LONDON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that it will report its interim results for the six months ended June 30, 2017 on Tuesday, August 8, 2017.

Verona Pharma will host an investment community conference call at 8:00 a.m. Eastern Daylight Time (1:00 pm British Summer Time) on August 8, 2017 to discuss the interim financial results and provide a clinical development update.

Analysts and investors may participate in the conference call by utilizing the conference ID: 4729485 and dialing the following numbers:

  • (877)280-2296 or (646)254-3367 for callers in the United States
  • 0800 279 4841 or 44(0)20 3427 1905 for callers in the United Kingdom
  • 0800 589 2674 or 49(0)69 2222 10624 for calls in Germany

Those interested in listening to the conference call live via the internet may do so by visiting the “Investors” page of Verona Pharma’s website at www.veronapharma.com and clicking on the webcast link.

A webcast replay of the conference call [audio] will be available on the “Investors” page of Verona Pharma’s website at www.veronapharma.com.

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com 
   
N+1 Singer (Nominated Adviser and UK Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / James White / Alex Laughton-Scott    
   
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie Cuthbert /
Natalie Garland-Collins
veronapharma@fticonsulting.com 
   
ICR, Inc. (US Media and Investor enquiries)  
James Heins Tel: +1 203-682-8251
  James.Heins@icrinc.com 
Stephanie Carrington Tel. +1 646-277-1282
  Stephanie.Carrington@icrinc.com 

 

Primary Logo

Verona Pharma plc

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us